Tenax Therapeutics Inc YBOC-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 06/30/22 CEST
0.26UNCH (UNCH)
52 week range
0.26 - 1.84
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.37
  • 52 Week High1.84
  • 52 Week High Date06/29/21
  • 52 Week Low0.26
  • 52 Week Low Date06/30/22

Key Stats

  • Market Cap7.82M
  • Shares Out25.21M
  • 10 Day Average Volume1,527.27
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-69.84

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.37
  • 52 Week High1.84
  • 52 Week High Date06/29/21
  • 52 Week Low0.26
  • 52 Week Low Date06/30/22
  • Market Cap7.82M
  • Shares Out25.21M
  • 10 Day Average Volume1,527.27
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-69.84

RATIOS/PROFITABILITY

  • EPS (TTM)-0.46
  • P/E (TTM)-0.57
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Tenax Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need. The Company's products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The Company's lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. TNX-201 is for...
Gerald Proehl
Independent Chairman of the Board
Christopher Giordano
President, Chief Executive Officer, Director
Eliot Lurier CPA
Interim Chief Financial Officer
Address
One Copley Parkway, Suite 490
Morrisville, NC
27560
United States